Efficacy and safety of remidazolam or propofol combined with remifentanil intravenous general anesthesia for hysteroscopy

Efficacy and safety of remidazolam or propofol combined with remifentanil intravenous general anesthesia for hysteroscopy: a prospective, double-blind, randomized, controlled clinical trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200062064

Enrollment

Unknown

Registered

2022-07-21

Start date

2022-07-22

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesiology

Interventions

propofol :propofol

Remazolam:Remazolam

Eligibility

Sex/Gender

Female

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 18-60 years old, ASAI-III

Exclusion criteria

Exclusion criteria: Patients with severe hypertension (systolic blood pressure = 200mmhg, or diastolic blood pressure = 120mmhg); Patients with difficult airway; Patients with severe heart, liver, lung, or kidney diseases; Patients with severe anemia, shock, metabolic disease, and electrolyte disorder; pregnant woman; Patients who are unable to communicate; Alcoholics and drug addicts; Patients with delayed gastric retention or gastric emptying; Patients who abuse hormones or narcotic analgesics; Persons who are allergic to the study drug.

Design outcomes

Secondary

Measure	Time frame
safety;	—

Primary

Measure	Time frame
efficacy;MOAA/S and BIS;	—

Countries

China

Contacts

Public ContactXuehai Guan

First Affiliated Hospital of Guangxi Medical University

guan_xh@allyun.com+86 18587697310

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026